Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in J Infect

Retrieve available abstracts of 92 articles:
HTML format

Single Articles

    November 2022
  1. ZHAO Y, Zhao Y, Zhou Y, Zhang Z, et al
    Inactivated COVID-19 vaccination and maternal renal function during early pregnancy: a retrospective cohort study of 6397 Chinese pregnant women.
    J Infect. 2022 Nov 22:S0163-4453(22)00676-4. doi: 10.1016/j.jinf.2022.

  2. YARCI-CARRION A, Esparcia-Pinedo L, Mateo-Jimenez G, Alfranca A, et al
    Effect of a SARS-CoV-2 booster vaccine dose on the immune response of adults with Down syndrome.
    J Infect. 2022 Nov 20:S0163-4453(22)00675-2. doi: 10.1016/j.jinf.2022.

  3. WANG X, Sima L
    Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.
    J Infect. 2022 Nov 20:S0163-4453(22)00674-0. doi: 10.1016/j.jinf.2022.
    PubMed     Abstract available

  4. WANG G, Zhao K, Han J, Hu Z, et al
    Safety and Immunogenicity of a Bivalent SARS-CoV-2 Recombinant Protein Vaccine, SCTV01C in Unvaccinated Adults: A Randomized, Double-blinded, Placebo-controlled, Phase I Clinical Trial.
    J Infect. 2022 Nov 17:S0163-4453(22)00649-1. doi: 10.1016/j.jinf.2022.

  5. MILLER P, Patel SR, Skinner R, Dignan F, et al
    Joint Consensus Statement on the Vaccination of Adult and Paediatric Haematopoietic Stem Cell Transplant Recipients. Prepared on Behalf of the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT), the Children's Cancer an
    J Infect. 2022 Nov 15. pii: S0163-4453(22)00646.
    PubMed     Abstract available

  6. MASHIMO Y, Yamazaki K, Kageyama T, Tanaka S, et al
    Germline variants of IGHV3-53 / V3-66 are determinants of antibody responses to the BNT162b2 mRNA COVID-19 vaccine.
    J Infect. 2022 Nov 2. pii: S0163-4453(22)00614.

    October 2022
  7. HE WQ, Gianacas C, Muscatello DJ, Newall AT, et al
    Effectiveness of influenza vaccination in reducing influenza-like illness and related antibiotic prescriptions in adults from a primary care-based case-control study.
    J Infect. 2022 Oct 23. pii: S0163-4453(22)00626.
    PubMed     Abstract available

  8. KANDEL C, Lee Y, Taylor M, Llanes A, et al
    Viral Dynamics of the SARS-CoV-2 Omicron Variant Among Household Contacts with 2 or 3 COVID-19 Vaccine Doses.
    J Infect. 2022 Oct 22. pii: S0163-4453(22)00625.
    PubMed     Abstract available

  9. NISHIKIMI A, Nakagawa T, Fujiwara M, Watanabe K, et al
    Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan.
    J Infect. 2022 Oct 20. pii: S0163-4453(22)00621.

  10. ZHENG Q, Wang M, Cheng Y, Liu J, et al
    Antibody response and safety of COVID-19 vaccine in peritoneal dialysis patients.
    J Infect. 2022 Oct 17. pii: S0163-4453(22)00612.

  11. NAZARETH J, Barr I, Sullivan SG, Goss C, et al
    Intra-season waning of immunity following the seasonal influenza vaccine in early and late vaccine recipients.
    J Infect. 2022 Oct 13. pii: S0163-4453(22)00604.

  12. LEE J, Park S, Kim JY, Lim SY, et al
    No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers.
    J Infect. 2022 Oct 9. pii: S0163-4453(22)00600.

    September 2022
  13. HUANG J, Xia L, Zhao Y, Wu X, et al
    Coronavirus disease 2019 vaccination and live birth outcome after fresh embryo transfer.
    J Infect. 2022 Sep 26. pii: S0163-4453(22)00552.

  14. AO G, Li A, Wang Y, Tran C, et al
    The effect of SARS-CoV-2 double vaccination on the outcomes of hemodialysis patients with COVID-19: a meta-analysis.
    J Infect. 2022 Sep 26. pii: S0163-4453(22)00553.

  15. YIN Y, Lin J, Yuan S, Tong S, et al
    A booster shot of vaccine against SARS-CoV-2 should be rigorously promoted and implemented in China.
    J Infect. 2022 Sep 25. pii: S0163-4453(22)00546.

  16. XU QY, Zheng XQ, Jia ZJ, Wu MJ, et al
    Developing new COVID-19 vaccine against the variants is urgently needed rather than boosters: A longitudinal cohort study.
    J Infect. 2022 Sep 12. pii: S0163-4453(22)00539.

  17. MOUSSAOUI ME, Desmecht S, Tashkeev A, Lambert N, et al
    Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naive people living with HIV.
    J Infect. 2022 Sep 9. pii: S0163-4453(22)00534.

  18. ATTI A, Insalata F, Carr EJ, Otter AD, et al
    Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: a nested case-control within the SIREN study.
    J Infect. 2022 Sep 8. pii: S0163-4453(22)00535.
    PubMed     Abstract available

  19. BEKKAT-BERKANI R, Fragapane E, Preiss S, Rappuoli R, et al
    Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.
    J Infect. 2022 Sep 7. pii: S0163-4453(22)00530.
    PubMed     Abstract available

  20. SHI T, Dai M, Liu F, Hu J, et al
    Dynamics of immune responses to inactivated COVID-19 vaccination over 8 months in China.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00521.

  21. DIMEGLIO C, Tremeaux P, Herin F, Da-Silva I, et al
    Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00522.

    August 2022
  22. GIDARI A, Schiaroli E, Sabbatini S, Bastianelli S, et al
    Impact of SARS-CoV-2 Omicron Variants on Serum Neutralization in a Cohort of Healthcare Workers Vaccinated with BNT162b2.
    J Infect. 2022 Aug 25. pii: S0163-4453(22)00507.

  23. LI K, Ruan F, Zhao Z, Guo Z, et al
    Comparative analysis of transmission and vaccine effectiveness in Omicron and Delta variant outbreaks in China.
    J Infect. 2022 Aug 22. pii: S0163-4453(22)00502.

  24. WAN EYF, Mok AHY, Yan VKC, Wang B, et al
    Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study.
    J Infect. 2022 Aug 16. pii: S0163-4453(22)00472.

    July 2022
  25. NOH JY, Cheong HJ, Kim WJ, Choi JY, et al
    Robust neutralizing antibody responses after single-dose BNT162b2 vaccination at long intervals from prior SARS-CoV-2 infection and ceiling effect with repeated vaccination: Running title: Optimal vaccination interval and ceiling effect.
    J Infect. 2022 Jul 31. pii: S0163-4453(22)00456.

  26. HAGIYA H, Hikita T, Habu T, Asada M, et al
    Poor vaccine responsiveness towards third-dose mRNA vaccine of COVID-19 in Japanese older people.
    J Infect. 2022 Jul 11. pii: S0163-4453(22)00413.

  27. YAN Y, Davgadorj C, Lyu C, Zhang S, et al
    Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: a cross-sectional study.
    J Infect. 2022 Jul 5. pii: S0163-4453(22)00407.

    June 2022
  28. XIAO J, Zhu Q, Yang F, Zeng S, et al
    The impact of enterovirus A71 vaccination program on hand, foot, and mouth disease in Guangdong, China:a longitudinal surveillance study.
    J Infect. 2022 Jun 26. pii: S0163-4453(22)00376.
    PubMed     Abstract available

  29. YIN Y, Li X, Qian C, Cheng B, et al
    Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study.
    J Infect. 2022 Jun 24. pii: S0163-4453(22)00374.

  30. NIYOMNAITHAM S, Toh ZQ, Licciardi PV, Wongprompitak P, et al
    Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: a randomized trial.
    J Infect. 2022 Jun 18. pii: S0163-4453(22)00370.

  31. LAZARUS R, Taucher C, Brown C, Corbic I, et al
    Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.
    J Infect. 2022 Jun 16. pii: S0163-4453(22)00361.
    PubMed     Abstract available

  32. WORSLEY CM, van der Mescht MA, Hoffman D, Meyer PWA, et al
    Decline in antibody responses to SARS-CoV-2 post-vaccination poses a risk to health care workers.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00360.

  33. KANG SW, Kim JY, Park H, Lim SY, et al
    Comparison of outward transmission potential between vaccinated and partially vaccinated or unvaccinated individuals with the SARS-CoV-2 delta variant infection.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00355.

  34. XU QY, Li QL, Jia ZJ, Wu MJ, et al
    Is the fourth COVID-19 vaccine dose urgently needed? Revelation from a prospective cohort study.
    J Infect. 2022 Jun 9. pii: S0163-4453(22)00356.

  35. CHEN CH, Janapatla RP, Su LH, Li HC, et al
    Incidence rates, emerging serotypes and genotypes, and antimicrobial susceptibility of pneumococcal disease in Taiwan: A multi-center clinical microbiological study after PCV13 implementation.
    J Infect. 2022;84:788-794.
    PubMed     Abstract available

  36. PAPAILIOU S, Soldatou A, Marmarinos A, Avgeris M, et al
    Inadequate protection against measles and rubella among pregnant women in Greece during the last measles outbreak.
    J Infect. 2022;84:e95-e97.

    May 2022
  37. NISHIKIMI A, Watanabe K, Watanabe A, Yasuoka M, et al
    Immune responses to COVID-19 vaccine BNT162b2 in workers at a research institute in Japan: 6-month follow-up survey.
    J Infect. 2022 May 20. pii: S0163-4453(22)00307.

  38. ZHANG YM, Liu XZ, Lin MM, Zan JC, et al
    Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients.
    J Infect. 2022 May 9. pii: S0163-4453(22)00260.

  39. VAN GRONINGEN KM, Dao BL, Gounder P
    Declines in invasive pneumococcal disease (IPD) during the COVID-19 pandemic in Los Angeles county.
    J Infect. 2022 May 9. pii: S0163-4453(22)00259.

  40. DIMEGLIO C, Migueres M, Chapuy-Regaud S, Da-Silva I, et al
    Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response.
    J Infect. 2022 May 7. pii: S0163-4453(22)00258.

  41. MARSAY L, Dold C, Paterson GK, Yamaguchi Y, et al
    Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.
    J Infect. 2022;84:658-667.
    PubMed     Abstract available

    April 2022
  42. JIMENEZ D, Martinez-Sanz J, Sainz T, Calvo C, et al
    Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00248.
    PubMed     Abstract available

  43. YADAV PD, Sapkal GN, Sahay RR, Patil DY, et al
    Reduced neutralizing antibody response in naive Covishield vaccinees against Omicron emphasizes booster vaccination.
    J Infect. 2022 Apr 21. pii: S0163-4453(22)00213.

  44. PANDIT P, Bhatt P, Sahay RR, Joshi Y, et al
    A case of breakthrough infection with SARS-CoV-2 Delta derivative and reinfection with Omicron variant in a fully vaccinated health care professional.
    J Infect. 2022 Apr 18. pii: S0163-4453(22)00205.

  45. LIU X, Munro APS, Feng S, Janani L, et al
    Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00200.
    PubMed     Abstract available

  46. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    Serum C reactive protein predicts humoral response after BNT162b2 booster administration.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00197.

  47. YADAV PD, Sahay RR, Agrawal S, Shete A, et al
    Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00193.

  48. LIU Y, Li P, Yang L, Li P, et al
    High vaccination coverage slows down genetic diversity of SARS-CoV-2.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00191.

  49. CHENG CY, Hsiao SH, Fang TC, Lin YC, et al
    SARS-CoV2 Antibody Response After a Third Dose of Heterologous ChAdOx1 nCoV-19 and Moderna Vaccine in Chronic Dialysis Patients.
    J Infect. 2022 Apr 7. pii: S0163-4453(22)00190.

  50. LIN J, Dobbins T, Wood JG, Bernardo C, et al
    Impact of a national immunisation program on herpes zoster incidence in Australia.
    J Infect. 2022;84:537-541.
    PubMed     Abstract available

    March 2022
  51. SCHILDGEN V, Lusebrink J, Schildgen O
    Compulsary SARS-CoV-2 (booster-) vaccination in healthcare facilities can not replace personal protection measures while dealing with vulnarable individuals.
    J Infect. 2022 Mar 23. pii: S0163-4453(22)00173.

  52. YADAV PD, Sapkal GN, Sahay RR, Patil DY, et al
    Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naive vaccinees.
    J Infect. 2022 Mar 19. pii: S0163-4453(22)00170.

  53. DIMEGLIO C, Loubes JM, Migueres M, Saune K, et al
    Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants.
    J Infect. 2022 Mar 17. pii: S0163-4453(22)00140.

  54. XIANG B, Yang L, Ye Z, Ren T, et al
    Vaccination of Susceptible Animals Against SARS-CoV-2.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00131.

  55. FERRE VM, Lebourgeois S, Chenane HR, Menidjel R, et al
    Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00126.

  56. BONNET B, Chabrolles H, Archimbaud C, Brebion A, et al
    Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination.
    J Infect. 2022 Mar 9. pii: S0163-4453(22)00132.

  57. GIMENEZ E, Albert E, Burgos JS, Peiro S, et al
    SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty(R) COVID-19 vaccine.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00124.
    PubMed     Abstract available

  58. BONGIOVANNI M, Spada E, De Angelis C, Liuzzi G, et al
    SARS-CoV-2: about reinfection, vaccination and neutralizing antibodies.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00125.

  59. SYED MA DR, A/Qotba HA Dr, Al Nuaimi AS Dr
    Effectiveness of COVID-19 vaccines in Qatar.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00121.

  60. SCHALTZ-BUCHHOLZER F, Bjerregard Oland C, Berendsen M, Bjerregaard-Andersen M, et al
    Maternal BCG primes for enhanced health benefits in the newborn.
    J Infect. 2022;84:321-328.
    PubMed     Abstract available

  61. AU WY, Ye C, Briner SL, Suarez GD, et al
    Systematic comparison between BNT162b2 and CoronaVac in the seroprotection against SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants.
    J Infect. 2022 Mar 1. pii: S0163-4453(22)00123.

    February 2022
  62. PUTRI DU, Lin CF, Hung CS, Huang CK, et al
    Distinct B and NKT cell Responses Shape the Delayed Response to ChAdOx1 nCoV-19 Vaccine in End-Stage Renal Disease.
    J Infect. 2022 Feb 28. pii: S0163-4453(22)00116.

  63. HAYASHI JY, Simizo A, Miyamoto JG, Costa LVS, et al
    Humoral and Cellular Responses to Vaccination with Homologous CoronaVac or ChAdOx1 and Heterologous Third Dose with BNT162b2.
    J Infect. 2022 Feb 27. pii: S0163-4453(22)00115.

  64. TANG K, Wu X, Luo Y, Wei Z, et al
    Meta-analysis of Immunologic response after COVID-19 mRNA vaccination in solid organ transplant recipients.
    J Infect. 2022 Feb 19. pii: S0163-4453(22)00081.

  65. SAHAY RR, Patil DY, Sapkal GN, Deshpande GR, et al
    SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera.
    J Infect. 2022 Feb 19. pii: S0163-4453(22)00082.

  66. FERRI S, Polidoro A, Ciacciarelli M, Ceratti U, et al
    Decline of immune humoral response after BNT162b2 Vaccine.
    J Infect. 2022 Feb 17. pii: S0163-4453(22)00076.

  67. TRE-HARDY M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, et al
    Assessment 2 months after the administration of a 3rd dose mRNA: A new variant-adapted vaccine is expected.
    J Infect. 2022 Feb 15. pii: S0163-4453(22)00073.

  68. LIU F, Wang H, Cao Y, Zhang N, et al
    Effectiveness of varicella vaccine in 1-year-old children: a matched case-control study.
    J Infect. 2022 Feb 11. pii: S0163-4453(22)00069.

  69. WESTROP SJ, Whitaker HJ, Powell AA, Power L, et al
    Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England.
    J Infect. 2022 Feb 4. pii: S0163-4453(22)00055.
    PubMed     Abstract available

  70. ESTOFOLETE CF, Fares GF, Banho CA, Sacchetto L, et al
    Predictors of death in COVID-19 vaccine breakthrough infections in Brazil.
    J Infect. 2022 Feb 2. pii: S0163-4453(22)00059.

    January 2022
  71. XU W, Tang J, Chen C, Wang C, et al
    Safety and Efficacy of the Covid-19 Vaccine in children andor adolescents: A meta-analysis.
    J Infect. 2022 Jan 30. pii: S0163-4453(22)00050.

  72. MATTIUZZI C, Lippi G
    COVID-19 vaccines efficacy in preventing or limiting SARS-CoV-2 infections.
    J Infect. 2022 Jan 30. pii: S0163-4453(22)00051.

  73. MENSAH AA, Lacy J, Stowe J, Seghezzo G, et al
    Evaluation of disease severity during SARS-COV-2 reinfection, January 2020 to April 2021, England: an observational study.
    J Infect. 2022 Jan 24. pii: S0163-4453(22)00010.
    PubMed     Abstract available

  74. DUCLOUX D, Bamoulid J, Chabannes M, Colladant M, et al
    Current vaccine strategies against SARS_CoV-2 only poorly protect kidney transplant recipients.
    J Infect. 2022 Jan 21. pii: S0163-4453(22)00020.

  75. FAUSTINI S, Shields A, Banham G, Wall N, et al
    Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00002.

  76. YANG Y, Gong X, Yang L, Li J, et al
    Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections or vaccinees.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00005.

  77. DE MICHELENA P, Torres I, Albert E, Bracho A, et al
    Impact of time elapsed since full vaccination on SARS-CoV-2 RNA load in Delta-variant breakthrough COVID-19.
    J Infect. 2022 Jan 8. pii: S0163-4453(22)00007.

  78. WHITAKER HJ, Tsang RS, Byford R, Andrews NJ, et al
    Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups.
    J Infect. 2022 Jan 3. pii: S0163-4453(21)00664.
    PubMed     Abstract available

  79. MARRAMS ARM, Kobayashi T, Suzuki H, Alsuhaibani M, et al
    Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis.
    J Infect. 2022 Jan 1. pii: S0163-4453(21)00658.
    PubMed     Abstract available

    December 2021
  80. MIN JY, Mwakingwe-Omari A, Riley M, Molo LY, et al
    The Adjuvanted Recombinant Zoster Vaccine Co-Administered with the 13-valent Pneumococcal Conjugate Vaccine in Adults Aged >/=50 Years: a Randomized Trial.
    J Infect. 2021 Dec 25. pii: S0163-4453(21)00651.
    PubMed     Abstract available

  81. COSTA R, Olea B, Bracho MA, Albert E, et al
    RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status.
    J Infect. 2021 Dec 22. pii: S0163-4453(21)00641.

  82. MANOLACHE NG, Ursachi V, Scohy A, Desmet C, et al
    Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases.
    J Infect. 2021 Dec 14. pii: S0163-4453(21)00597.

  83. MAK WA, Koeleman JGM, van der Vliet M, Keuren F, et al
    SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study.
    J Infect. 2021 Dec 9. pii: S0163-4453(21)00593.
    PubMed     Abstract available

    November 2021
  84. OESER C, Whitaker H, Linley E, Borrow R, et al
    Large increases in SARS-CoV-2 seropositivity in children in England: Effects of the Delta wave and vaccination.
    J Infect. 2021 Nov 30. pii: S0163-4453(21)00584.

  85. LUCIDARME J, Bai X, Lekshmi A, Clark SA, et al
    Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - first real-world data: Meningococcal B following 4CMenB.
    J Infect. 2021 Nov 25. pii: S0163-4453(21)00579.
    PubMed     Abstract available

  86. ALDERSON MR, Arkwright PD, Bai X, Black S, et al
    Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review.
    J Infect. 2021 Nov 24. pii: S0163-4453(21)00578.
    PubMed     Abstract available

  87. LEBOURGEOIS S, Menidjel R, Chenane HR, Ferre VM, et al
    Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.
    J Infect. 2021 Nov 19. pii: S0163-4453(21)00556.

  88. GIMENEZ E, Alberola J, Torres I, Albert E, et al
    Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty(R) COVID-19 vaccine.
    J Infect. 2021 Nov 2. pii: S0163-4453(21)00542.

    October 2021
  89. CHONG Y, Tani N, Goto T, Yonekawa A, et al
    Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents.
    J Infect. 2021 Oct 20. pii: S0163-4453(21)00508.

  90. GUPTA A, Bhoyar RC, Mirza S, Jolly B, et al
    SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker.
    J Infect. 2021 Oct 19. pii: S0163-4453(21)00506.

  91. ANIS E, Haas EJ, Indenbaum V, Singer SR, et al
    A prolonged, nationwide measles outbreak despite very high vaccination coverage in Israel, 2018-19.
    J Infect. 2021 Oct 6. pii: S0163-4453(21)00497.
    PubMed     Abstract available

    September 2021
  92. FERRE VM, Lebourgeois S, Menidjel R, Collin G, et al
    Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine.
    J Infect. 2021 Sep 29. pii: S0163-4453(21)00488.

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.